Nec Corporation

Pfizer Corporation

Kyowa Hakko Kirin Co., Limited

Naoki Sawada

Masayuki Ikeda

Daisuke Yokoi

Ichirou Akimoto

Yousuke Motohashi

Chia-Yang Lin

Margaret Ann Marshall

Shobha Chowdary Potluri

Shihao Chen

LiFen Lee

Denis Healy

A failure analysis deviceis provided with an identification unitthat discriminates whether a predetermined failure has occurred on the basis of a learning model for discriminating the presence or absence of an occurrence of the predetermined failure learned by using a cause attribute which is associated with a cause of the predetermined failure and on the basis of a value of the attribute, and that identifies the cause of the predetermined failure discriminated to have occurred and countermeasures therefor.

Failure analysis device, failure analysis method, and failure analysis program

A first prediction unitpredicts the amount of future communication quality deterioration or the presence or absence of occurrence of future communication quality deterioration in a communication section between one communication device and another communication device communicably connected to the one communication device by using a first learning model generated on the basis of first attributes being attributes related to a cause of communication quality deterioration in the communication section. A second prediction unitpredicts the amount of future communication quality deterioration or the presence or absence of occurrence of future communication quality deterioration outside the communication section regarding one communication device by using a second learning model generated on the basis of second attributes being attributes related to a cause of communication quality deterioration outside the communication section regarding the one communication device.

Communication quality deterioration prediction system, method, and program

The present disclosure describes combination therapies comprising an antibody which specifically binds to human CCR4 and a selective 4-1BB agonist, and the use of the combination therapies for the treatment of cancer.

Method of treating cancer with a combination of an anti-CCR4 antibody and a 4-1BB agonist

Growing community of inventors

Tokyo, Japan

Naoki Sawada